Radiopharm Enters into Strategic Collaboration with Lantheus and Assumes Pd-l1 Licensing Agreement from Nanomab

Radiopharm Theranostics announced that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types inluding NSCLC.